Australia Peanut Allergy Treatment Market Size & Outlook
Australia peanut allergy treatment market, 2018-2030 (US$M)
Related Markets
Australia peanut allergy treatment market highlights
- The Australia peanut allergy treatment market generated a revenue of USD 9.7 million in 2023 and is expected to reach USD 24.1 million by 2030.
- The Australia market is expected to grow at a CAGR of 13.9% from 2024 to 2030.
- In terms of segment, epinephrine was the largest revenue generating drug class in 2023.
- Immunotherapies is the most lucrative drug class segment registering the fastest growth during the forecast period.
Peanut allergy treatment market data book summary
| Market revenue in 2023 | USD 9.7 million |
| Market revenue in 2030 | USD 24.1 million |
| Growth rate | 13.9% (CAGR from 2023 to 2030) |
| Largest segment | Epinephrine |
| Fastest growing segment | Immunotherapies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
| Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
Other key industry trends
- In terms of revenue, Australia accounted for 2.0% of the global peanut allergy treatment market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China peanut allergy treatment market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 56.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peanut Allergy Treatment Market Scope
Peanut Allergy Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia peanut allergy treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 47.42% in 2023. Horizon Databook has segmented the Australia peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
In Australia, the prevalence of peanut allergy is relatively high, affecting nearly 3% of children of 1 year. However, there is a positive trend as approximately 20% of these children tend to outgrow their peanut allergy over time. This suggests that peanut allergy is a concern in the country, but there is hope for improvement, especially as children grow older.
It is essential to recognize that peanut allergy can be a significant health issue for a portion of the population, especially children. This trend highlights the need for continued research, improved diagnostic methods, & effective treatments to manage and, where possible, reduce peanut allergies in Australia.
Reasons to subscribe to Australia peanut allergy treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia peanut allergy treatment market databook
-
Our clientele includes a mix of peanut allergy treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia peanut allergy treatment market , including forecasts for subscribers. This country databook contains high-level insights into Australia peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia peanut allergy treatment market size, by drug class, 2018-2030 (US$M)
Australia Peanut Allergy Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
